13F Holdings
中文EN

QNRX Quoin Pharmaceuticals Ltd.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1671502

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-42.3%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-142.5%
ROA-95.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets17.4%
Debt / equity0.00x
Current ratio7.20x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.96x
Accruals ratio-3.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue————$0
R&D expense$9.80M$3.60M$3.31M$2.67M$1.56M
SG&A expense$6.49M$5.93M$6.07M$6.58M$4.50M
Interest expense————$1.09M
Pretax income-$15.80M-$8.96M———
Net income-$15.80M-$8.96M-$8.69M-$9.38M-$21.46M
EPS (basic)————-0.01
EPS (diluted)————-0.01
Weighted avg. shares (diluted)————1.58B
Balance sheet
Cash & equivalents$3.82M$3.62M$2.40M$2.86M$7.48M
Short-term investments$14.93M$10.43M———
Current assets$20.01M$14.93M$11.29M$13.37M$8.20M
Intangibles$383,334$483,334$583,334$704,561$808,604
Total assets$20.39M$15.71M$12.17M$14.46M$9.36M
Current liabilities$5.55M$4.18M$3.58M$3.53M$4.58M
Total liabilities$7.27M$6.50M$6.51M$7.05M$8.70M
Shareholders' equity$13.12M$9.20M$5.66M$7.41M$657,032
Shares outstanding52.44M8.95M987,220403,8873.35B
Cash flow statement
Operating cash flow-$13.54M-$7.86M-$7.86M-$8.48M-$5.72M
Investing cash flow-$4.28M-$1.89M$2.19M-$10.15M-$625,000
Financing cash flow$18.01M$10.97M$5.22M$14.01M$13.50M
Stock-based compensation$1.15M$1.26M$1.09M$764,007$0

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.